TY  - JOUR 
AU  - Penalver, F. J.
AU  - Marquez, J. A.
AU  - Duran, S.
AU  - Giraldo, P.
AU  - Martin, A.
AU  - Montalban, C.
AU  - Sancho, J. M.
AU  - Ramirez, M. J.
AU  - Terol, M. J.
AU  - Capote, F. J.
AU  - Gutierrez, A.
AU  - Sanchez, B.
AU  - Lopez, A.
AU  - Salar, A.
AU  - Rodriguez-Caravaca, G.
AU  - Canales, M.
AU  - Caballero, M. D.
AU  - Bello López, José Luis
AU  - Carbonell, F.
AU  - Bordas, S. F.
AU  - Lopez, P. F.
AU  - Persona, E. P.
AU  - Guillermo, A. L.
AU  - Martin, R. H.
AU  - Mayans, J. R.
AU  - Palomera, L.
AU  - Ceballos, E. P.
AU  - Hernandez, J. A. Q.
AU  - Grau, R. R.
AU  - de la Cruz, F.
AU  - Salinas, A. S.
PY  - 2019
SN  - 2045-7634
UR  - http://hdl.handle.net/20.500.11940/15703
AB  - BACKGROUND: Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. METHODS: This phase II trial evaluated the efficacy and safety of response-adapted...
LA  - eng
KW  - Immunotherapy
KW  - Adult
KW  - Mitoxantrone
KW  - Middle Aged
KW  - Humans
KW  - Dexamethasone
KW  - Drug Resistance
KW  - Lymphoma
KW  - Salvage Therapy
KW  - Aged
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Antineoplastic Agents
TI  - Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial
DO  - 10.1002/cam4.2555
T2  - Cancer Medicine
M2  - 6955
KW  - CHUS
VL  - 8
ER  -